Relief Cardiovascular Secures $12 Million Series A Funding to Advance Novel Transcatheter Implant for Heart Failure Management

Relief Cardiovascular Announces Completion of $12 Million Series A Financing

This round of financing was co-led by Broadview Ventures and Advent Life Sciences, with participation from Pacific Health Investment, Heartwork Capital Fund, and an undisclosed multinational strategic company.These funds will support further product development and the launch of the company's first-in-human feasibility study, aimed at evaluatingThe safety and effectiveness of the Relief system, a transcatheter smart implant designed to monitor and regulate renal vein pressure, offering a new approach for fluid management in heart failure.

As part of the financing, Shahzad Malik, General Partner at Advent Life Sciences, and Maria Berkman, Head of Medical Technology at Broadview Ventures, will join the company's board of directors.

"Heart failure continues to impose a significant burden on patients and the healthcare system. The Relief System addresses critical gaps in patient care, and we are proud to collaborate with the Relief Cardiovascular team to advance this new therapy into clinical practice."

“Relief Cardiovascular's innovative volume management approach addresses the unmet need in diuretic-resistant heart failure, and the Relief system’s ability to dynamically modulate renal venous pressure offers the potential to redefine treatment and improve outcomes for patients with limited options.。”

The Relief system uses a transcatheter implant with an innovative "puller" mechanism to reduce renal vein pressure, paired with integrated sensors that autonomously capture renal vein pressure and multiparameter data. The system provides actionable data to optimize fluid management and offers tailored, device-driven interventions for treatment.The ability of the Relief system to integrate renal pressure monitoring and therapeutic adjustment represents a promising advancement in heart failure volume management.By implementing data-driven adjustments, the Relief system offers patients more personalized and effective care, especially those with diuretic resistance.

"As we advance the Relief system into human clinical studies, this financing represents a key milestone for us," said Alex Cooper, CEO of Relief Cardiovascular. "We are honored to have the support of world-class investors and clinicians, as well as industry veterans like Michael Minogue. With Shahzad and Maria joining our board, our team is poised to transform the management and treatment of heart failure."